Medical Devices
Technology
Health

Baxter

$77.18
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.41 (-0.53%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Baxter and other stocks, options, ETFs, and crypto commission-free!

About

Baxter International, Inc. provides portfolio of essential renal and hospital products, including acute and chronic dialysis, sterile IV solutions, infusion systems and devices, parenteral nutrition therapies; premixed and oncolytic injectable, bio surgery products and anesthetics, drug reconstitution systems; and pharmacy automation, software and services. It operates through the following segment: Americas, Europe, Middle East & Africa and Asia-Pacific. Read More The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.

Employees
50,000
Headquarters
Deerfield, Illinois
Founded
1931
Market Cap
39.80B
Price-Earnings Ratio
25.87
Dividend Yield
1.11
Average Volume
3.29M
High Today
$77.68
Low Today
$76.87
Open Price
$77.68
Volume
741.91K
52 Week High
$78.38
52 Week Low
$61.05

Collections

Medical Devices
Technology
Health
Medical
Software Service
US
North America

News

Yahoo FinanceMar 19

Baxter (BAX) Upgraded to Buy: Here's What You Should Know

Baxter (BAX) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. Baxter International (BAX) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The Zacks rating relies solely on a company's changing earnings picture. It tracks ...

37
Yahoo FinanceMar 19

Baxter's (BAX) New Tie Up to Boost Acute Therapies Business

Baxter International Inc. BAX and bioMérieux recently announced an agreement to develop future biomarkers for prompt identification and treatment of acute kidney injury (“AKI”) at the International Symposium on Intensive Care and Emergency Medicine. This is expected to boost Baxter’s Acute Therapies business apart from fortifying its foothold in the global renal care market. However, following the announcement, shares of this Zacks Rank #2 (Buy) company fell 0.2% to $76.95 at close. Details about the deal...

4
BusinessWireMar 19

Baxter and bioMérieux Announce Collaboration to Improve Identification and Treatment of Acute Kidney Injury

DEERFIELD, Ill. & MARCY L’ÉTOILE, France--(BUSINESS WIRE)--Regulatory News: Baxter International Inc. (NYSE:BAX), a global leader in acute care, and bioMérieux (Paris:BIM), a world leader in the field of in vitro diagnostics, announced an agreement to develop future biomarkers with the goal to rapidly identify and inform treatment of acute kidney injury (AKI). The announcement was made at the International Symposium on Intensive Care and Emergency Medicine (ISICEM) this week. “We’re committed to improving...

9

Earnings

$0.56
$0.64
$0.72
$0.80
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Available Apr 25, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.